{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=63&state=Colorado",
    "query": {
      "state": "Colorado",
      "city": "Aurora",
      "page": 63
    },
    "page_size": 10
  },
  "pagination": {
    "page": 63,
    "page_size": 10,
    "total_count": 7459,
    "total_pages": 746,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=64&state=Colorado&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=62&state=Colorado&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T10:11:37.281Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03893682",
      "title": "A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "CG-806",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aptose Biosciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2019-04-30",
      "completion_date": "2024-05-17",
      "has_results": false,
      "last_update_posted_date": "2025-03-07",
      "last_synced_at": "2026-11-19T10:11:37.281Z",
      "location_count": 30,
      "location_summary": "Los Angeles, California • Monterey, California • Redondo Beach, California + 25 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Redondo Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03893682"
    },
    {
      "nct_id": "NCT04828824",
      "title": "Premature Discontinuation of Contraceptive Implants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Contraception Behavior"
      ],
      "interventions": [
        {
          "name": "Ethinyl Estradiol / Norgestimate Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "23 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 23 Years · Female only"
      },
      "enrollment_count": 600,
      "start_date": "2021-06-18",
      "completion_date": "2025-11-12",
      "has_results": true,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-11-19T10:11:37.281Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04828824"
    },
    {
      "nct_id": "NCT02142959",
      "title": "RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Omaveloxolone Lotion 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Lotion 3%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Lotion",
          "type": "DRUG"
        },
        {
          "name": "3D conformal radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 187,
      "start_date": "2014-06-30",
      "completion_date": "2015-04-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-11-19T10:11:37.281Z",
      "location_count": 27,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 23 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02142959"
    },
    {
      "nct_id": "NCT00384488",
      "title": "Automated Diabetes Prevention Program",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pre-Diabetes"
      ],
      "interventions": [
        {
          "name": "Interactive Voice Response System (IVR)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2004-05",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2006-10-06",
      "last_synced_at": "2026-11-19T10:11:37.281Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00384488"
    },
    {
      "nct_id": "NCT04089761",
      "title": "Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Migraine"
      ],
      "interventions": [
        {
          "name": "Nerivio",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Theranica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 60,
      "start_date": "2019-10-01",
      "completion_date": "2020-05-24",
      "has_results": true,
      "last_update_posted_date": "2021-02-25",
      "last_synced_at": "2026-11-19T10:11:37.281Z",
      "location_count": 12,
      "location_summary": "Aurora, Colorado • Hialeah, Florida • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04089761"
    },
    {
      "nct_id": "NCT02304458",
      "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Melanoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Rhabdomyosarcoma",
        "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Hodgkin Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Melanoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Rhabdomyosarcoma",
        "Stage III Cutaneous Melanoma AJCC v7",
        "Stage IIIA Cutaneous Melanoma AJCC v7",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Months to 30 Years"
      },
      "enrollment_count": 140,
      "start_date": "2015-03-30",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2023-10-17",
      "last_synced_at": "2026-11-19T10:11:37.281Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02304458"
    },
    {
      "nct_id": "NCT05868226",
      "title": "PRE-ISPY Phase I/II Oncology Platform Program",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "Metastatic Cancer",
        "Metastatic Breast Cancer",
        "Metastatic",
        "HER2-positive Metastatic Breast Cancer",
        "HER2 Mutation-Related Tumors",
        "HER-2 Protein Overexpression",
        "HER2-negative Breast Cancer",
        "Triple Negative Breast Cancer",
        "HR Positive",
        "Hormone Receptor-positive Breast Cancer",
        "Estrogen Receptor Positive Tumor",
        "Progesterone Receptor-positive Breast Cancer",
        "Hormone Receptor Negative Breast Carcinoma",
        "Solid Tumor",
        "Solid Tumor, Adult",
        "Solid Carcinoma",
        "HER2 Low Breast Cancer",
        "HER2 Low Breast Carcinoma",
        "ER Positive Breast Cancer",
        "PR-positive Breast Cancer",
        "Minimal Residual Disease",
        "Colo-rectal Cancer",
        "Colon Cancer",
        "Rectal Cancer",
        "ctDNA Monitoring",
        "Colorectal Neoplasms",
        "Colonic Neoplasms",
        "Rectal Neoplasms",
        "Neoplasm, Residual",
        "Adenocarcinoma of Colon",
        "Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "ALX148",
          "type": "DRUG"
        },
        {
          "name": "Fam-Trastuzumab Deruxtecan-Nxki",
          "type": "DRUG"
        },
        {
          "name": "Zanidatamab",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib",
          "type": "DRUG"
        },
        {
          "name": "TTX-MC138",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QuantumLeap Healthcare Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2023-02-15",
      "completion_date": "2031-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-11-19T10:11:37.281Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05868226"
    },
    {
      "nct_id": "NCT04763278",
      "title": "Validation of User Needs of the Point Digit With Partial Hand Amputees",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Amputation; Traumatic, Hand"
      ],
      "interventions": [
        {
          "name": "Point Digit",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Point Designs",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2021-01-07",
      "completion_date": "2022-03-30",
      "has_results": true,
      "last_update_posted_date": "2024-09-27",
      "last_synced_at": "2026-11-19T10:11:37.281Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Lafayette, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lafayette",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04763278"
    },
    {
      "nct_id": "NCT03451825",
      "title": "Phase I/II Study of Avelumab in Pediatric Cancer Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory or Relapsed Solid Tumors",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 21,
      "start_date": "2018-03-07",
      "completion_date": "2021-07-27",
      "has_results": true,
      "last_update_posted_date": "2024-06-24",
      "last_synced_at": "2026-11-19T10:11:37.281Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • The Bronx, New York",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03451825"
    },
    {
      "nct_id": "NCT00444925",
      "title": "Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "fesoterodine fumarate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "tolterodine tartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1712,
      "start_date": "2007-04",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2015-03-24",
      "last_synced_at": "2026-11-19T10:11:37.281Z",
      "location_count": 41,
      "location_summary": "Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 36 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Orangevale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00444925"
    }
  ]
}